1. Home
  2. SUPN vs WLY Comparison

SUPN vs WLY Comparison

Compare SUPN & WLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$26.85

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo John Wiley & Sons Inc.

WLY

John Wiley & Sons Inc.

SELL

Current Price

$50.46

Market Cap

2.4B

ML Signal

SELL

Company Overview

Basic Information
Metric
SUPN
WLY
Founded
2005
1807
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Books
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.4B
IPO Year
2014
1994

Fundamental Metrics

Financial Performance
Metric
SUPN
WLY
Price
$26.85
$50.46
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $60.50
N/A
AVG Volume (30 Days)
★ 1.7M
338.7K
Earning Date
10-29-2026
12-03-2026
Dividend Yield
N/A
★ 2.73%
EPS Growth
★ 8100.00
171.90
EPS
★ 2.78
N/A
Revenue
$1,239,000,000.00
★ $1,796,103,000.00
Revenue This Year
$23.01
$4.68
Revenue Next Year
$15.28
$3.13
P/E Ratio
N/A
★ N/A
Revenue Growth
4.29
★ 4.51
52 Week Low
$26.74
$28.38
52 Week High
$59.68
$57.45

Technical Indicators

Market Signals
Indicator
SUPN
WLY
Relative Strength Index (RSI) 19.93 55.32
Support Level N/A $48.69
Resistance Level $51.59 $54.07
Average True Range (ATR) 2.21 1.50
MACD -1.14 -0.18
Stochastic Oscillator 8.37 58.11

Price Performance

Historical Comparison
SUPN
WLY

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

About WLY John Wiley & Sons Inc.

John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning, which includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.

Share on Social Networks: